



16 October 2025

**Crystal Amber Fund Limited  
("Crystal Amber", the "Company" or the "Fund")**

**Investor Presentation by Morphic Medical Inc**

The Board of Crystal Amber is pleased to announce that Morphic Medical Inc. ("MMI"), the medical device company in which the Fund owns 96.7% of the issued share capital, will be conducting a live investor presentation this morning via the Investor Meet Company platform, followed immediately by a Q&A session.

This online event will take place at **10:30am today (Thursday 16 October 2025)**.

The presentation will be hosted by Mike Gutteridge, MMI's CEO and President, with opening remarks from Chris Waldron, Crystal Amber's Chairman.

The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

To register, please visit: <https://www.investormeetcompany.com/crystal-amber-fund-limited/register-investor>

Investors who already follow CRYSTAL AMBER FUND LIMITED on the Investor Meet Company platform will automatically be invited.

No new material information will be disclosed during the event. The slides of the presentation will subsequently be made available on [morphicmedical.com](http://morphicmedical.com).

For further enquiries please contact:

**Sodali & Co - Financial PR adviser to Morphic Medical Inc**

Russ Lynch / Sam Austrums

Tel: 020 7250 1446

[morphicmedical@sodali.com](mailto:morphicmedical@sodali.com)

**Crystal Amber Fund Limited**

Chris Waldron (Chairman)

Tel: 01481 742 742

[www.crystalamber.com](http://www.crystalamber.com)

**Allenby Capital Limited - AIM Nominated Adviser to Crystal Amber Fund Limited**

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

**Winterflood Investment Trusts - Broker to Crystal Amber Fund Limited**

Joe Winkley/Neil Langford

Tel: 020 3100 0160

**Crystal Amber Advisers (UK) LLP - Investment Adviser to Crystal Amber Fund Limited**

Richard Bernstein

Tel: 020 7478 9080

**ABOUT MORPHIC MEDICAL**

[Morphic Medical](http://morphicmedical.com) is the developer of RESET®, the first incision-free, endoscopically delivered therapy designed to treat obesity and related metabolic disorders such as type 2 diabetes.

RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP-1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.

RESET addresses a major global health need, with an estimated 93 million adults in Europe alone living with obesity and type 2 diabetes. It has been endorsed in the latest clinical guidelines for obesity treatment by both the European Society for Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE) - a strong validation from the medical community.

Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts.

For more information, please visit [morphicmedical.com](http://morphicmedical.com) or follow on [X \(formerly Twitter\)](#) and / or [LinkedIn](#).

conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPKPBNNBDBKKD